Dapiglutide: The Dual GLP-1/GLP-2 Obesity Peptide That Bet on the Gut — and Got Paused (July 2, 2026)
Table of Contents
Two gut hormones, one peptide
Almost every obesity drug making headlines works through a single gut hormone receptor: GLP-1. Semaglutide and tirzepatide (which adds GIP) built an entire industry on it. Dapiglutide, Zealand Pharma's peptide known internally as ZP7570, tried something different — a single once-weekly molecule that activates two sibling receptors, GLP-1 and GLP-2. GLP-1 does the familiar work: curbing appetite, slowing the stomach and improving blood-sugar control. GLP-2 is the quieter cousin, released from the same intestinal L-cells, and it is trophic to the gut lining — the same biology behind short-bowel-syndrome drugs like teduglutide, glepaglutide and apraglutide. The bet was that pairing them could deliver weight loss and something GLP-1 alone does not: a stronger intestinal barrier.
Why the gut barrier mattered to the thesis
Obesity is not just excess weight; it comes with chronic, low-grade systemic inflammation. One proposed driver is a 'leaky' gut barrier that lets bacterial products cross into circulation — sometimes called metabolic endotoxemia — nudging the immune system into a persistent, smoldering state. GLP-2's trophic effect on the intestinal mucosa is exactly the kind of mechanism that could tighten that barrier. So dapiglutide's design carried a dual promise: lose weight through GLP-1, and address obesity-related comorbidities driven by inflammation through GLP-2. It was a genuinely differentiated idea in a field crowded with GLP-1 look-alikes.
The data: a slow start, then a real signal
The clinical story was not a straight line. The first-in-obesity Phase 2a proof-of-concept trial (NCT05788601), published in the Lancet journal eClinicalMedicine in February 2026, randomized 54 adults to dapiglutide 4 mg, 6 mg or placebo for 12 weeks. It was safe and well tolerated — but it did not beat placebo for weight loss at those doses. Rather than abandon the program, Zealand pushed the dose. A 13-week Phase 1b cohort reported roughly 8.3% mean weight loss, and a 28-week cohort escalating up to 26 mg once weekly reported a mean 11.6% reduction in body weight versus just 0.2% for placebo, with gastrointestinal side effects typical of the incretin class. That June 2025 topline, presented at the American Diabetes Association's 85th Scientific Sessions, showed the drug clearly worked when pushed high enough.
Then Zealand paused it
In November 2025, despite that double-digit result, Zealand Pharma announced it was pausing dapiglutide's development. The reasoning was strategic, not safety-related: management concluded that 11.6% weight loss — while real — did not clearly separate dapiglutide from newer incretin-based therapies in an increasingly crowded metabolic market, and that advancing it would require a long, expensive clinical path with limited room to differentiate. The company framed it as 'active portfolio management,' redirecting resources to candidates it considers more differentiated: the amylin analog petrelintide and the GLP-1/glucagon dual agonist survodutide, both heading toward key 2026 readouts. Zealand was explicit that the decision reflected competitive positioning, not a clinical or safety flag.
Why a paused drug still matters
It is tempting to write off dapiglutide as a failure, but that misreads it. First, it is a clean case study in dose-response: a Phase 2a that looked like placebo became an 11.6% result once the dose climbed — a reminder not to judge an incretin peptide by an underdosed early trial. Second, its GLP-2 arm keeps a real scientific question open: can strengthening the gut barrier meaningfully reduce obesity-related inflammation, and is that worth pursuing in dual agonists even if pure weight loss is now table stakes? Third, it illustrates the brutal bar a new obesity peptide now faces — beating not today's drugs but tomorrow's. The mechanism did not fail; the market moved.
Keeping it honest
For anyone reading about dapiglutide, the accurate summary is this: it is investigational, not approved anywhere, and its development is currently paused. Its pivotal-style Phase 2a did not beat placebo; the impressive weight-loss numbers came from higher-dose early-phase cohorts. It is a subcutaneous, clinical-stage biologic-class peptide studied under medical supervision — not a self-experimentation 'research peptide,' and any vendor claiming to sell 'dapiglutide' or 'ZP7570' is illegitimate. Its lasting value is conceptual: a well-designed attempt to make an obesity peptide do double duty on weight and the gut, and a candid example of how portfolio strategy — not just biology — decides which peptides move forward.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled proof-of-concept trial — eClinicalMedicine (2026) Source
- [2] Zealand Pharma announces positive topline results from 28-week Phase 1b trial with dapiglutide (June 2025) Source
- [3] Dapiglutide (program paused) — Zealand Pharma pipeline Source
- [4] Zealand hits pause on dual GLP-1/GLP-2 asset — Fierce Biotech (Nov 2025) Source
Related Articles
Glepaglutide: The Long-Acting GLP-2 Peptide Trying to Free Short Bowel Patients From IV Nutrition (June 30, 2026)
Glepaglutide is a long-acting GLP-2 analog dosed once or twice weekly that helps the remaining gut absorb more nutrients in short bowel syndrome — cutting, and sometimes eliminating, the need for IV nutrition. Here is where it stands in 2026 after positive Phase 3 data, an FDA Complete Response Letter, and a European filing.
Apraglutide: The Once-Weekly GLP-2 Peptide for Short Bowel Syndrome — and Why the FDA Wants One More Trial (June 30, 2026)
Apraglutide is a once-weekly GLP-2 analog that helps the remaining gut absorb more in short bowel syndrome — the least frequent dosing of any drug in its class. Its Phase 3 STARS trial worked, but in 2026 it still needs an FDA-required confirmatory trial. Here is where it stands.